2010 full-year results 3 March 2011 - UCB

More documents

Recommendations

Info

Development pipeline with significant progress Central Nervous System (CNS) Neupro ® (rotigotine) Adv. Parkinson's disease (U.S.) Neupro ® (rotigotine) Restless legs syndrome (U.S.) Xyrem ® (sodium oxybate) Fibromyalgia (EU) Vimpat ® (lacosamide) Epilepsy – monotherapy (U.S.) Vimpat ® (lacosamide) Epilepsy – monotherapy (EU) brivaracetam Epilepsy – adj. therapy Vimpat ® (lacosamide) Epilepsy – Paediatric adj. therapy Vimpat ® (lacosamide) Epilepsy – adj. therapy PGTCS UCB0942 (PPSI) Epilepsy Phase 1 Phase 2 Phase 3 Regulatory status first results Results H2 2011 Results Q2 2013 Results Q4 2014 Results H1 2013 Filed CRL* November Dec 2008 2008 CRL* Dec 2008 CRL1 April Filed 2010 � � � * Complete Response Letter 40
Development pipeline with significant progress Immunology Cimzia ® (certolizumab pegol) Rheumatoid arthritis (Japan) Cimzia ® (certolizumab pegol) Ankylosing spondylitis Cimzia ® (certolizumab pegol) Psoriatic arthritis epratuzumab SLE Cimzia ® (certolizumab pegol) Juvenile rheumatoid arthritis CDP7851 (anti-sclerostin) Post-menopausal osteoporosis CDP7851 (anti-sclerostin) Fracture healing olokizumab (anti-IL 6) Rheumatoid arthritis CDP7657 (anti CD40L) SLE Phase 1 Phase 2 Phase 3 Results Q2 2011 Results 2012 Results Q3 2012 Positive results Results Q4 2011 Results Q4 2011 Results H1 2014 Regulatory status � � 41
Page 1 and 2: 2010 full-year results 3 March 2011
Page 3 and 4: UCB: to be patient-centric global b
Page 5 and 6: 203 000 patients have now been trea
Page 7 and 8: U.S. Business Greg Duncan, Presiden
Page 9 and 10: Cimzia ® provides a fast response
Page 11 and 12: Cimzia ® in rheumatoid arthritis -
Page 13 and 14: Vimpat ® U.S. When monotherapy is
Page 15 and 16: UCB’s status as the company with
Page 17 and 18: Physicians report Vimpat ® is the
Page 19 and 20: Cimzia ® Fast response for predict
Page 21 and 22: Cimzia ® roll-out in Europe and Re
Page 23 and 24: Vimpat ® in epilepsy Roll-out in E
Page 25 and 26: Neupro ® roll-out in Europe and Re
Page 27 and 28: Neupro ® - rotigotine transdermal
Page 29 and 30: 2010 Financial Performance Detlef T
Page 31 and 32: Net sales of major and new products
Page 33 and 34: Recurring EBITDA Consistent solid u
Page 35 and 36: 2010 cash flows FY 2009 cash € 46
Page 37 and 38: 2011 financial outlook Revenue is e
Page 39: Advancing the pipeline Iris Loew-Fr
Page 43 and 44: Brivaracetam in epilepsy New Phase
Page 45 and 46: Additional external pipeline option
Page 47 and 48: UCB NewMedicines strategy and busin
Page 49 and 50: Attrition rates of failed Phase 3 c
Page 51 and 52: UCB2892 (H3 antagonist) January 201
Page 53 and 54: Significant Pipeline Q2 January pip
Page 55 and 56: UCB's Sustainable Growth Roch Doliv
Page 57 and 58: UCB's sustainable future growth Cim
Page 59 and 60: Appendix 59 59
Page 61 and 62: Geographic and therapeutic breakdow
Page 63 and 64: 2010 balance sheet € million Cash
Page 65 and 66: Shareholder structure 1 Strong and
Page 67 and 68: Cimzia ® in further arthritis indi
Page 69 and 70: CDP7851 in bone loss disorders Nove
Page 71 and 72: Vimpat ® in epilepsy Increasing pa
Page 73: Your UCB Investor Relations team An

2010 full-year results 3 March 2011 - UCB

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?